全文获取类型
收费全文 | 999篇 |
免费 | 58篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 56篇 |
妇产科学 | 43篇 |
基础医学 | 108篇 |
口腔科学 | 12篇 |
临床医学 | 62篇 |
内科学 | 230篇 |
皮肤病学 | 6篇 |
神经病学 | 93篇 |
特种医学 | 58篇 |
外科学 | 181篇 |
综合类 | 28篇 |
预防医学 | 33篇 |
眼科学 | 11篇 |
药学 | 41篇 |
中国医学 | 3篇 |
肿瘤学 | 92篇 |
出版年
2023年 | 5篇 |
2022年 | 11篇 |
2021年 | 18篇 |
2020年 | 11篇 |
2019年 | 26篇 |
2018年 | 26篇 |
2017年 | 21篇 |
2016年 | 28篇 |
2015年 | 25篇 |
2014年 | 29篇 |
2013年 | 50篇 |
2012年 | 69篇 |
2011年 | 74篇 |
2010年 | 31篇 |
2009年 | 38篇 |
2008年 | 51篇 |
2007年 | 55篇 |
2006年 | 51篇 |
2005年 | 34篇 |
2004年 | 57篇 |
2003年 | 50篇 |
2002年 | 41篇 |
2001年 | 29篇 |
2000年 | 34篇 |
1999年 | 24篇 |
1998年 | 6篇 |
1997年 | 6篇 |
1996年 | 10篇 |
1995年 | 7篇 |
1994年 | 6篇 |
1992年 | 7篇 |
1991年 | 5篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 7篇 |
1985年 | 16篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 9篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1971年 | 4篇 |
1970年 | 2篇 |
排序方式: 共有1061条查询结果,搜索用时 265 毫秒
1.
Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function 总被引:6,自引:2,他引:4
Nampoory M. R. N.; Johny K. V.; Al-Hilali N.; Seshadri M. S.; Kanagasabhapathy A. S. 《Nephrology, dialysis, transplantation》1996,11(1):177-181
BACKGROUND: Following successful renal transplantation, blood erythropoietin(Epo) levels peak in two phases during the first 23 months,and blood haemoglobin/haematocrit (Hb/Hct) levels are restoredto normal in a period of 26 months. However, some transplantrecipients continue to remain anaemic in spite of normal graftfunction and in the absence of recognizable causes. The roleof endogenous Epo production in the causation of anaemia insuch patients is poorly understood and has been investigatedin this study. METHODS: Twenty-three post-renal transplant recipients with stable normalrenal function were studied. Eleven of these patients had normalHb/Hct levels (group 1) and served as control for the rest 12patients with anaemia (group 2). Patients included in group2 had no readily recognizable cause for their anaemia. Otherlaboratory and clinical findings were similar in both groups.Patients with erythrocytosis were excluded. Serum Epo levelswere measured in all patients. Five patients in group 2 weretreated with recombinant human erythropoietin (rHuEpo) and theirerythropoietic response was assessed. rHuEpo was discontinuedwhen the target Hb/Hct levels (lowest normal range) were achievedand the patients were followed up for a further period of 912months. RESULTS: Five patients in group 1 had normal expected serum Epo levelswhereas the other six patients had inappropriately high serumEpo levels with respect to their Hb/Hct status suggestive ofrelative Epo resistance. Serum Epo levels in allpatients except two in group 2 were low indicative of Epodeficiency. The two exceptional patients in group 2 hadhigher serum Epo levels in the presence of anaemia suggestiveof relative Epo resistance. All five patients treated with rHuEpo responded adequately byachieving normal Hb/Hct levels. Three of them were originallyEpo deficient and they reached target Hb/Hct levelsin a mean period of 4 weeks, requiring a mean cumulative rHuEpodose of 428.3 units/kg. The other two patients with higher initialserum Epo levels, and considered to be Epo resistant,required an average of 11 weeks of treatment and a mean cumulativerHuEpo dose of 1582.5 units/ kg, indicating an increased Epodemand. On cessation of therapy the Hb/Hct levels fell in allfive patients to pretreatment values in 6 months. CONCLUSIONS: There are important variations in the endogenous Epo productionin renal transplant patients with normal renal function, thecause of which is not clear. Epo deficiency and relative Eporesistance play a causative role for anaemia in some post-renaltransplant recipients with stable normal renal function. Theyrespond adequately to rHuEpo administration. 相似文献
2.
J Rajeev Shoba Srinath Y C J Reddy M G Shashikiran Satish Chandra Girimaji Shekhar P Seshadri D K Subbakrishna 《Revue canadienne de psychiatrie》2003,48(1):52-55
OBJECTIVE: Recent studies of patients with juvenile bipolar disorder report low rates of recovery and high rates of chronicity. However, we lack data on the short-term outcome. This study examines the pattern of recovery from the index episode in an aggressively treated juvenile sample. METHOD: We assessed 25 subjects (< 16 years) with a diagnosis of mania, using the Diagnostic Interview for Children and Adolescents-Revised) (DICA-R), Young Mania Rating Scale (YMRS), and Children's Global Assessment Scale (CGAS) at intake and at 3 and 6 months. We studied the time taken to recover from the index episode, the level of functioning, and the factors predicting them. RESULTS: After 6 months, 24 (96%) subjects had recovered from the index manic episode. The median time to recovery was 27 days. Total episode length was significantly longer among those with previous affective episodes. CONCLUSIONS: The findings suggest that juvenile-onset mania has high rates of recovery and low rates of chronicity. These differences from the existing literature need further exploration. 相似文献
3.
4.
C Romano K Williams S DePriest R Seshadri G R Marshall M Israel P B Molinoff 《Molecular pharmacology》1992,41(4):785-792
Systematic series of monoamines, diamines, and triamines were used to define the structural requirements for interaction at the polyamine recognition site of the N-methyl-D-aspartate receptor complex. Effects of amines on binding of [3H]MK-801 to washed synaptic plasma membranes were measured in the presence of L-glutamate and glycine (100 microM each), in the absence or presence of spermine (10 microM). Linear aliphatic monoamines of methylene chain length up to 12 (dodecylamine) did not interact with the polyamine recognition site. Nonspecific inhibition of binding was observed at high concentrations of the longer monoamines. alpha,omega-Diamines of methylene chain length 2 (1,2-diaminoethane, DA2) through 12 (1,12-diaminododecane, DA12) had varying actions, depending on chain length. The shortest diamines (DA2 and DA3) acted as weak partial agonists, enhancing the binding of [3H[MK-801. Intermediate-length diamines (DA4-DA7) were selective polyamine antagonists, having little or no effect on binding of [3H]MK-801 measured in the absence of spermine but inhibiting binding measured in the presence of spermine. The longest diamines tested (DA8-DA12) acted as inverse agonists; they inhibited binding in the absence or presence of spermine, and this inhibition was blocked by the selective polyamine antagonist diethylenetriamine. Computer modeling of conformations of the diamines quantitatively documented that 1) these molecules are flexible and 2) long diamines may easily adopt conformations with inter-nitrogen distances mimicking those of short diamines. The cis and trans isomers of 1,4-diaminocyclohexane are inflexible, conformationally restricted diamines with markedly different actions. The cis isomer was a partial agonist and the trans isomer was an antagonist at the polyamine recognition site. Triamines of general structure NH2(CH2)3NH(CH2)xNH2 (TRI[3,x]), in which x = 3-12, were synthesized and tested for activity at the polyamine recognition site. Despite the large range of size, TRI[3,3] through TRI[3,9] were all fully polyamine agonists of similar potency. TRI[3,10] was a partial agonist, whereas TRI[3,12] inhibited binding of [3H]MK-801. Diethylenetriamine did not attenuate the effect of TRI[3,12]. Based on the results of the radioligand binding studies and the computer analysis, a model of the polyamine recognition site is proposed. 相似文献
5.
Mervyn Israel Trevor W. Sweatman Ramakrishnan Seshadri Yoshihiro Koseki 《Cancer chemotherapy and pharmacology》1989,25(3):177-183
Summary
N-Benzyladriamycin-14-valerate (AD 198) is a new lipophilic adriamycin (ADR) analogue that shows marked therapeutic superiority to ADR in murine tumor model systems yet differs mechanistically from ADR in a number of ways. Among its other properties, AD 198 produces a delayed but profound effect on cell-cycle progression and a pattern of continuing DNA damage in cultured cells briefly exposed to the drug. Using radiolabeled drug forms and radioassays combined with HPLC separation and fluorimetric detection techniques, aspects of drug accumulation, biotransformation, and retention in cultured human CEM leukemic lymphocytes were studied, in part to determine a possible pharmacologic basis for the latent effects seen with this drug. In addition, the cellular pharmacology of AD 198 and ADR were comparatively examined under identical experimental conditions. When CEM cells were incubated with drug at equi-growth inhibitory/minimally cytotoxic concentrations (AD 198, 1.0 M; ADR, 0.1 M), a number of differences were apparent. Under conditions of continuous 24-h drug exposure, a slow cellular accumulation and equilibration was observed with ADR (cell: medium equilibrium, 1:11 after 4–6 h), whereas the uptake of AD 198 was rapid and extensive (cell: medium equilibrium, 3:1 within 30 min). In drug-retention studies, when cells were pretreated at the same drug concentrations as before (AD 198 for 1 h; ADR for 4 h) and then transferred to drug-free media, both compounds re-equilibrated their intracellular drug content with the fresh media, losing about 50% of their respective anthracycline levels. Liquid chromatographic analysis of ADR-treated cultures under both sets of conditions showed the parent drug to be the only intracellular anthracycline species, whereas analysis of AD 198-treated cultures revealed two fluorescent signals corresponding to the parent drug and its 14-deesterified biotransformation product,N-benzyladriamycin (AD 288). Levels of AD 288 rose from 2% of the total intracellular anthracycline content immediately on drug admixture to 61% following 24 h continuous drug exposure and to 69% at 24 h in cells exposed to drug for 1 h and then continued in drug-free media for 24 h. At all times, the balance of the intracellular anthracycline fluorescence was attributable to the parent drug; no ADR was detectable in AD 198-treated cells by either fluorescence detection or radioassay. Thus, AD 198 is not a prodrug form of ADR, and the in vitro effects of this agent, including the latent effects on cell-cycle inhibition and DNA damage seen in cells following short-term drug exposure, can be explained on the basis of the high levels of active parent drug and biotransformation product that accumulate and persist in the cells.Abbreviations ADR
adriamycin (doxorubicin)
- AD 198
N-benzyladriamycin-14-valerate
- AD 288
N-benzyladriamycin
- AD 32
N-trifluoroacetyladriamycin-14-valerate
- AD 143
N-trifluoroacetyladriamycin-14-0-hemiadipate
- AD 41
N-trifluoroacetyladriamycin
- [14C]-AD 198
[benzyl]--methylene-14C]-N-benzyladriamycin-14-valerate
- [14C]-ADR
[14-14C]-adriamycin
- HPLC
high-performance liquid chromatography
- TLC
thin-layer chromatography
- DMSO
dimethylsulfoxide
- S-MEM
Eagle's minimum essential medium for suspension culture
- PBS
phosphate-buffered saline (pH 7.0) 相似文献
6.
7.
8.
9.
Ronald L. Arenson Dev P. Chakraborty Sridhar B. Seshadri Harold L. Kundel 《Journal of digital imaging》2003,16(1):142-162
Picture archiving and communication systems (PACS) are expected to convert film-based radiology into a computer-based digital environment, with associated cost savings and improved physician communication. The digital workstation will be used by physicians to display these soft-copy images; however, difficult technical challenges must be met for the workstation to compete successfully with the familiar viewbox. Issues relating to image perception and the impact on physicians practice must be carefully considered. The spatial and contrast resolutions required vary according to imaging modality, type of procedure, and class of user. Rule-based software allows simple physician interaction and speeds image display. A consensus appears to be emerging concerning the requirements for the PACS workstation. Standards such as the American College of Radiology/National Electrical Manufacturers Association Digital Imaging and Communication Standard are facilitating commercial applications. Yet much careful study is needed before PACS workstations will be fully integrated into radiology departments.
Abbreviations: CRT = cathode ray tube, H&D = Hurter and Drifield, PACS = picture archiving and communication system, ROC = receiver operating characteristic, S/N = signal-to-noise ratio. Partially supported by grant HL-33332 from the National Heart, Lung, and Blood institute, U.S. Public Health Service. Address reprint requests to R.L.A. Copyright © 1990 by the Radiological Society of North America. Radiology 176:303-315, 1990. Reprinted with permission. 相似文献
10.
Metabolism and elimination of rhodamine 123 in the rat 总被引:1,自引:0,他引:1
Trevor W. Sweatman Ramakrishnan Seshadri Mervyn Israel 《Cancer chemotherapy and pharmacology》1990,27(3):205-210
Summary Little is known of the pharmacology of rhodamine 123 (RH-123), an agent reported to have carcinoma-selective experimental antitumor activity. Accordingly, using a high-performance liquid chromatographic assay system with fluorescence detection, we examined the plasma decay and the biliary and urinary elimination of parent drug and metabolites in female Sprague-Dawley rats receiving RH-123 at an intravenous dose (5 mg/kg) equivalent to the therapeutic dose used in murine tumor models. Following drug administration to unconscious animals, plasma levels of drug-associated fluorescence fell in a triphasic manner (t1/2, 15 min; t1/2, 1 h; t1/2, 4.7 h). In plasma, unchanged drug predominated but lower levels of the deacylated metabolite rhodamine 110 (RH-110) and two unknowns were also detectable throughout the study. Drug fluorescence was recovered extensively in both urine and bile. In unconscious animals with ureteral cannulae, urinary excretion (11.4% of the dose in 6 h) occurred predominantly as unchanged RH-123 (97% of the total), with low levels of RH-110 (2.4%) and two unknowns (<0.6% combined) also being present. Similarly dosed conscious animals (without surgical intervention) housed in metabolic cages showed a comparable pattern of urinary excretion, with 11.9% of the drug dose being recovered in 6 h and 21.9%, by 48 h. Biliary drug elimination accounted for 8% of the delivered dose in 6 h in unconscious animals and for 11% by 36 h in conscious animals fitted with biliary cannulae. In contrast to urinary excretion, in which unchanged drug predominated, only 50% of the fluorescence recovered in bile was attributable to RH-123. The remainder was due to a number of products that were detectable throughout the study. Of these, one present at significant levels was identified as a glucuronide conjugate of RH-123, based on the liberation of parent drug when the purified metabolite was incubated with -glucuronidase or hydrolyzed with 1 N hydrochloric acid. Further studies with a radiolabeled form of RH-123 are necessary to establish the identity of the remaining unknowns disclosed in this work.This work was supported in part by research grants CA 44890 (T.W.S.) and CA 37082 (M.I.) from the National Cancer Institute, National Institutes of Health, United States Public Health Service 相似文献